<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Upregulation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) has been implicated in the pathogenesis of several inflammatory conditions, including <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic agents such as antibodies or soluble TNF-alpha receptor analogs, which block TNF-alpha activity are a recent addition to the therapeutic armamentarium for the conditions </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a patient who developed <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> complicated by <z:hpo ids='HP_0100806'>sepsis</z:hpo> after receiving etanercept, a TNF-alpha receptor analog, for the treatment of <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001876'>Pancytopenia</z:hpo> resolved within 3 wk of discontinuing etanercept </plain></SENT>
<SENT sid="4" pm="."><plain>To our knowledge, this is the first report of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> associated with TNF-alpha blockade </plain></SENT>
</text></document>